- Klíčová slova
- proočkovanost,
- MeSH
- ekonomika a organizace zdravotní péče MeSH
- infekce papilomavirem epidemiologie imunologie prevence a kontrola MeSH
- lidé MeSH
- mladiství MeSH
- nádory etiologie prevence a kontrola MeSH
- rizikové faktory MeSH
- vakcinace statistika a číselné údaje MeSH
- vakcíny proti papilomavirům * ekonomika terapeutické užití MeSH
- Check Tag
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- novinové články MeSH
- zprávy MeSH
- Geografické názvy
- Česká republika MeSH
OBJECTIVES: The aim of the study was to evaluate the immune status of young people from the Vojvodina province, Serbia, through the detection of IgG antibodies specific for the L1 protein of HPV types 6, 11, 16, and 18 contained in quadrivalent vaccine. METHODS: The study enrolled 514 healthy persons of both genders, aged between 18 and 30 years. All potential participants were informed about the project's aims by trained interviewers before venous blood collection. Also, participants completed a specially designed anonymous questionnaire to identify socio-demographic characteristics and individual behaviours associated with HPV seroprevalence. VPL HPV L1-specific IgG antibodies were measured using a semi-quantitative HPV IgG ELISA kit (Dia.Pro, Italy). RESULTS: A total of 472 (91.8%) young subjects had no detectable antibodies against high- and low-risk HPV types covered by the quadrivalent vaccine. A slightly higher number of seropositive individuals were detected in the age group of 26-30 years compared to younger than 25. Multivariate analysis showed that the number of lifetime sexual partners was the most powerful predictor of HPV seropositivity (OR = 3.483, 95% CI: 1.294-9.379). CONCLUSIONS: Obtained data point out low levels of naturally induced HPV-specific serum antibodies among the target population in the Vojvodina province. The present work highlights the significance and potential benefits of HPV vaccination. Routine HPV vaccination should be the public health priority in our country and should be included in the national immunization programme as soon as possible.
- MeSH
- dospělí MeSH
- imunoglobulin G MeSH
- infekce papilomavirem * epidemiologie prevence a kontrola MeSH
- kombinované vakcíny MeSH
- lidé MeSH
- lidské papilomaviry MeSH
- mladiství MeSH
- mladý dospělý MeSH
- protilátky virové MeSH
- séroepidemiologické studie MeSH
- vakcíny proti papilomavirům * MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Jugoslávie MeSH
- Srbsko MeSH
- MeSH
- dysplazie děložního hrdla * epidemiologie patologie MeSH
- infekce papilomavirem epidemiologie patologie MeSH
- komplikace těhotenství patologie virologie MeSH
- konizace děložního čípku metody MeSH
- lidé MeSH
- těhotenství MeSH
- vedení porodu metody MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- MeSH
- Alphapapillomavirus patogenita MeSH
- infekce papilomavirem epidemiologie prevence a kontrola MeSH
- karcinom MeSH
- kondylomata akuminata epidemiologie prevence a kontrola MeSH
- kontrola infekčních nemocí MeSH
- lidé MeSH
- nádory děložního čípku epidemiologie prevence a kontrola MeSH
- preexpoziční profylaxe * ekonomika statistika a číselné údaje MeSH
- prekancerózy epidemiologie prevence a kontrola MeSH
- vakcíny proti papilomavirům * aplikace a dávkování MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- přehledy MeSH
Current knowledge about human papillomavirus (HPV) infection in psoriasis patients treated with biologics is limited. In this study we evaluated the prevalence of oral and genital HPV infection in psoriasis patients treated with biologics or topical therapy for at least 6 months. The presence of HPV DNA in oral rinse and genital smears was evaluated. In total, 267 patients who met the inclusion criteria and agreed to participate were enrolled: 110 (41.2%) on topical therapy, 84 (31.5%) on anti-TNF-alpha therapy, 31 (11.6%) on anti-IL-12/23 therapy and 42 (15.7%) on anti-IL-17 therapy. The presence of genital HPV infection was detected in 34.6% of men receiving anti-TNF-α treatment, in 25.0% of patients on anti-IL-12/23 and 18.8% of patients on anti-IL-17 therapy. The difference in prevalence was not statistically different from men on topical treatment (26.3%). Prevalence of oral HPV infection was higher across all of the biologic groups (11.9% for anti-TNF-α, 12.9% for anti-IL-12/23 and 19.0% for anti-IL-17) compared to patients on topical therapy (7.3%), but statistically significant only for anti-IL-17 (p < 0.05). The presence of oral HPV infection in patients treated with biologics was significantly higher (44.0%) in patients on long-term biologic treatment (>8 years) compared to patients taking biologics for a shorter period (9.1%; p < 0.01). Our results suggest that patients on biologics for psoriasis have a higher prevalence of oral HPV infection compared to patients on topical treatment. Long-term treatment with biologics seems to be associated with a higher prevalence of oral HPV infection, independent of previous conventional immunosuppressive therapy.
- MeSH
- biologická terapie MeSH
- biologické přípravky * škodlivé účinky MeSH
- infekce papilomavirem * diagnóza epidemiologie MeSH
- inhibitory TNF MeSH
- lidé MeSH
- Papillomaviridae MeSH
- pohlavní orgány MeSH
- psoriáza * farmakoterapie epidemiologie MeSH
- sexuálně přenosné nemoci * MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- MeSH
- infekce papilomavirem * epidemiologie přenos MeSH
- lidé MeSH
- prevalence MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
